Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly

Pasireotide long-acting release is effective in achieving bioche mical control and reducing tumour volume in patients with acromegaly inadequately controll ed by first-line therapy. As part of a long-term, real-world study at our centre, 20 of 50 patients receiving pasireotide benefited from a reduc...

Full description

Bibliographic Details

Published in:	Endocrine Connections
Main Authors:	Nelma Veronica Marques, Luiz Eduardo Armondi Wildemberg, Monica R Gadelha
Format:	Article
Language:	English
Published:	Bioscientifica 2023-09-01
Subjects:	acromegaly pasireotide long-term hyperglycaemia dose reduction
Online Access:	https://ec.bioscientifica.com/view/journals/ec/12/10/EC-23-0155.xml